Low-molecular-weight heparin prophylaxis of deep vein thrombosis for older patients with restricted mobility: Propensity analyses of data from two multicentre, cross-sectional studies

Drugs and Aging

Volumn 26, Issue 3, 2009, Pages 263-271

  Labarère, José ^a,b   Sevestre, Marie Antoinette ^b,c   Belmin, Joël ^d   Legagneux, Annie ^e   Barrellier, Marie Thérèse ^f   Thiel, Hélène ^g   Le Roux, Philippe ^h   Pernod, Gilles ^b   Bosson, Jean Luc ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL CHARLES FOIX   (France)

^e Saint L General Hospital   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h La Roche sur Yon Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

AGED; AGING; ARTICLE; BLEEDING; COMPRESSION THERAPY; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; FEMALE; HIGH RISK PATIENT; HUMAN; IMMOBILIZATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHYSICAL MOBILITY; PHYSIOTHERAPY; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CONTROLLED CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MOBILITY LIMITATION; RISK FACTORS; VENOUS THROMBOSIS;

EID: 64749089428     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200926030-00007     Document Type: Article

References (30)

1. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost 2007 Oct; 98 (4): 756-4
2. Spencer FA, Gore JM, Lessard D, et al. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 2008 Feb; 168 (4): 425-30
3. Stein PD, Hull RD, Kayali F, et al. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004 Nov; 164 (20): 2260-5
4. Spyropoulos AC, Merli G. Management of venous thromboembolism in the elderly. Drugs Aging 2006 Aug; 23 (8): 651-71
5. Bosson JL, Labarere J, Sevestre MA, et al. Deep vein thrombosis in elderly patients hospitalized in subacute care facilities: a multicenter cross-sectional study of risk factors, prophylaxis, and prevalence. Arch Intern Med 2003 Nov; 163 (21): 2613-8
6. Labarere J, Bosson JL, Sevestre MA, et al. Thromboprophylaxis with graduated compression stockings for elderly inpatients: more evidence is needed. J Thromb Haemost 2006 Aug; 4 (8): 1838-40
7. Sellier E, Labarere J, Sevestre MA, et al. Risk factors for deep vein thrombosis in older patients: a multicenter study with systematic compression ultrasonography in postacute care facilities in France. J Am Geriatr Soc 2008 Feb; 56 (2): 224-30
8. Bosson JL, Labarere J, Barrellier MT, et al. Practice guidelines for the prevention of venous thromboembolism in elderly patients hospitalized in subacute care and rehabilitation facilities. J Mal Vasc 2003 Oct; 28 (4): 209-18
9. Labarere J, Bosson JL, Sevestre MA, et al. Intervention targeted at nurses to improve venous thromboprophylaxis. Int J Qual Health Care 2007 Oct; 19 (5): 301-8
10. Sellier E, Labarere J, Bosson JL, et al. Effectiveness of a guideline for venous thromboembolism prophylaxis in elderly post-acute care patients: a multicenter study with systematic ultrasonographic examination. Arch Intern Med 2006 Oct; 166 (19): 2065-71
11. Murtaugh CM, Litke A. Transitions through postacute and long-term care settings: patterns of use and outcomes for a national cohort of elders. Med Care 2002 Mar; 40 (3): 227-36
12. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 Suppl. 3: 338-400
13. Labarere J, Bosson JL, Sevestre MA, et al. Graduated compression stocking thromboprophylaxis for elderly inpatients: a propensity analysis. J Gen Intern Med 2006 Dec; 21 (12): 1282-7
14. Labarere J, Bosson JL, Brion JP, et al. Validation of a clinical guideline on prevention of venous thromboembolism in medical inpatients: a before-and-after study with systematic ultrasound examination. J Intern Med 2004 Oct; 256 (4): 338-48
15. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999 Aug; 150 (4): 327-33
16. Trewet CB, Shireman TI, Rigler SK, et al. Do ACE inhibitors/angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. Drugs Aging 2007 Nov; 24 (11): 945-55
17. Eikelboom JW, Quinlan DJ, Douketis JD. Extendedduration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001 Jul; 358 (9275): 9-15
18. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001 Nov; 135 (10): 858-69
19. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003 Jun; 14 (4): 341-6
20. Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005 Feb; 165 (3): 341-5
21. Labarere J, Bosson JL, Bergmann JF, et al. Agreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practices: a cross-sectional study of 1,032 medical inpatients. J Gen Intern Med 2004 Aug; 19 (8): 849-55
22. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999 Sep; 341 (11): 793-800
23. Di Minno G, Tufano A. Challenges in the prevention of venous thromboembolism in the elderly. J Thromb Haemost 2004 Aug; 2 (8): 1292-8
24. Chaggar PS, Channer KS. Current issues in thromboprophylaxis in the elderly. Drugs Aging 2008; 25 (12): 1049-60
25. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000 Jun; 342 (25): 1887-92
26. Austin PC. The performance of different propensity score methods for estimating marginal odds ratios. Stat Med 2007 Jul; 26 (16): 3078-94
27. Vaitkus PT, Leizorovicz A, Cohen AT, et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005 Jan; 93 (1): 76-9
28. Kearon C. Natural history of venous thromboembolism. Circulation 2003 Jun; 107 Suppl. 1: 22-30
29. Fareed J, Hoppensteadt D, Schultz C, et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins: impact on the therapeutic profile. Curr Pharm Des 2004; 10 (9): 983-99
30. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol 2003 Apr; 121 (1): 12-20